Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma (LuminICE-203)

This study enrolling people who recurrent (has come back) or refractory (did not respond to treatment) classical Hodgkin lymphoma or CD30-positive peripheral T-cell lymphoma (PTCL). The purpose of this study is to learn about the effectiveness and safety of a new study drug called AFM13 when used in combination with a new cell therapy called AB-101. The study will also look at how the body processes this combination of drugs (called "pharmacokinetics").